Stockreport

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]

Vincerx Pharma, Inc.  (VINC) 
PDF Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate (ADC); preliminary data anticipated on or around the 2024 European Hematology Assoc [Read more]